Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Targeted radionuclide therapy of somatostatin receptor (SST)-expressing tumors is only partially addressed by the established somatostatin analogs having an affinity for the SST subtype 2 (SST2). Aiming to target a broader spectrum of tumors, we evaluated the bis-iodo-substituted somatostatin analog...

Full description

Bibliographic Details
Main Authors: Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, Melpomeni Fani
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Molecules
Subjects:
radiolabeled somatostatin analogs
SST2
SST5
Lu-177
targeted radionuclide therapy
neuroendocrine tumors
Online Access:https://www.mdpi.com/1420-3049/25/18/4155

Internet

https://www.mdpi.com/1420-3049/25/18/4155

Similar Items